Valeant Pharmaceuticals International Inc. surprised investors Tuesday and maintained its full-year guidance, setting a goal for the second half that will require the drugmaker to substantially raise its sales and profits.
As part of a planned turnaround, Valeant plans to sell assets that the company thinks will be worth about $8 billion, will renegotiate terms with lenders and will reorganize its business into three main segments as it tries to stabilize sales of several important but struggling products.
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant18
17:41 Ford to Record Pre-Tax Loss of $3 Billion in 201617
14:14 Ford expects $2B net income drop due to pension change15
14:53 Netflix fueled by original programming, even as its costs hold earnings back, analysts say16